Adrian Gottschalk, Foghorn Therapeutics CEO (Flagship via YouTube)
June 28, 2023 11:11 AM EDT
R&D

With just one re­sponse in 47 pa­tients, Foghorn stops work on lead can­di­date in ad­vanced eye can­cer

Lei Lei Wu

News Reporter

Foghorn Ther­a­peu­tics said Wednes­day morn­ing that it was stop­ping fur­ther work on an ex­per­i­men­tal drug for a rare ad­vanced eye can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

Biotech VC firm out­lines plans for $100M fund

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

FDA OKs the first-ever self-ad­min­is­tered vac­cine, for flu

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times